NewsRoom Articles - Page 64 of 174

FridayAug 05, 2022 10:15 am

Combining Immunotherapy with Anti-Rejection Drugs Can Treat Cancer, Prevent Kidney Transplant Rejection

Most kidney transplant patients usually stop taking their immunosuppressive drugs before starting cancer immunotherapy treatment to diminish the chances of their immune systems attacking the transplanted organs. However, a new study has found that combining standard antirejection medication and immune checkpoint inhibitors may benefit kidney transplant patients who suffer from terminal cancer. Immune checkpoint inhibitors are drugs designed to block checkpoints, which are proteins that prevent immune responses in the body from being too strong. Checkpoints also prevent T-cells from eliminating cancer cells. Blocking these checkpoints allows T-cells to eradicate cancer cells more effectively. The study’s objective was to look…

ThursdayAug 04, 2022 12:16 pm

Study Finds That Ketogenic Diet May Help Patients with Brain Cancer

New research has found that a ketogenic diet is feasible and safe for individuals with astrocytomas. A ketogenic diet is low in carbohydrates and high in fat. Astrocytomas are brain tumors that usually begin in cells known as astrocytes, which support nerve cells and occur in the brain or spinal cord. For their study, the researchers recruited 25 patients with astrocytomas who were each required to follow the Atkins diet and fast intermittently during an eight-week period. The modified ketogenic diet includes foods such as fish, butter, heavy cream, eggs, leafy green vegetables and bacon. The participants visited a dietician…

ThursdayAug 04, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits Another long-standing concern among service personnel is the treatment of concussive brain injuries Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on…

ThursdayAug 04, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market

CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study — particularly for one who remains cancer-free more than 15 years later CNS is enrolling patients in the United States, Italy, France, Spain, and Switzerland, for the global Phase 2 clinical trial to measure Berubicin’s potential to match or exceed the effectiveness of Lomustine, a…

WednesdayAug 03, 2022 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership…

WednesdayAug 03, 2022 10:49 am

Research Finds That Tourism, Travel May Boost Mental Health

A new study has suggested that tourism should be viewed as an industry that offers real health benefits, in addition to being viewed as a recreational experience. The study, which was conducted by researchers at the Center for Precision Health at the Edith Cowan University in collaboration with the School of Business and Law, discovered that various aspects of being on holiday could have a positive influence on individuals with mental health conditions. Dr. Jun Wen, the study’s lead researcher, stated that the diverse team of experts on public health, tourism and marketing looked into how tourism could benefit individuals…

TuesdayAug 02, 2022 1:00 pm

Study Finds That Difficulty Sleeping, Financial Stressors Increase Mental Health Risk in University Students

New research on student well-being in the pandemic period has identified sleep difficulties and worsened financial situation as indicators of people with a heightened risk of developing mental health conditions. The findings, which were reported in the “BJPsychOpen” journal, will be useful to institutions of higher learning because they can help identify students with a high risk of developing mental health conditions and offer enhanced support to those students. For their study, researchers at the University of Warwick carried out a survey of more than 500 young adults who weren’t in higher education and almost 900 university students, between July…

TuesdayAug 02, 2022 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses

Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on their immune system The AditxtScore(TM) system is initially focused on providing customers with reports looking into their vulnerability and immune response to SARS-CoV-2 and its known variants Every 9 minutes, a person is…

TuesdayAug 02, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising CNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the efficacy and safety of Berubicin for the treatment of GBM The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy CNS…

MondayAug 01, 2022 11:15 am

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to age Odyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal cavity The PRV-002 drug is expected to offer reprieve to people suffering from concussion by potentially preventing long-term consequences of the condition The drug is currently undergoing evaluation as part of a Phase I study that has so far shown that it is well tolerated…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Combining Immunotherapy with Anti-Rejection Drugs Can Treat Cancer, Prevent Kidney Transplant Rejection

Study Finds That Ketogenic Diet May Help Patients with Brain Cancer

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Research Finds That Tourism, Travel May Boost Mental Health

Study Finds That Difficulty Sleeping, Financial Stressors Increase Mental Health Risk in University Students

Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search